p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers

Journal of Surgical Oncology

Volumn 63, Issue 2, 1996, Pages 87-90

  Ichikawa, Daisuke ^a   Yamaguchi, Toshiharu ^a   Shirasu, Morio ^a   Kitamura, Kazuya ^a   Inazawa, Johji ^a   Abe, Tatsuo ^a   Takahashi, Toshio ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

apoptosis; cancer therapy; p53; sensitivity

Indexed keywords

FLUOROURACIL; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME 17P; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; POINT MUTATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECTUM CANCER; TUMOR SUPPRESSOR GENE;

ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEVER; FLUOROURACIL; GENES, P53; HETEROZYGOTE; HUMANS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SUPPOSITORIES;

EID: 0029907844     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199610)63:2<87::AID-JSO3>3.0.CO;2-K     Document Type: Article

References (25)

1. Minsky BD, Mies C, Recht A, et al.: Resectable adenocarcinoma of rectosigmoid and rectum, I:Patterns of failure and survival. Cancer 61:1408-1416, 1988.
2. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264(11): 1444-1450, 1990.
3. Takahashi T, Horie H, Kojima O, et al.: Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer. Surgery Today 23:1043-1048, 1993.
4. Ichikawa D, Takahashi T, Yoshioka Y, et al.: Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia and 5-fluorouracil suppository. Am J Surg 171:346-350, 1996.
5. Wyllie AH: The biology of cell death in tumours. Anticancer Res 5:131-136, 1985.
6. Sellin KS, Cohen J: Gene induction by X-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139:3199-3206, 1987.
7. Harmon BV, Takano YS, Winterfound CM, et al.: The role of apoptosis in the response of cells and tumors to mild hyperthermia. Int J Radiat Biol 59:489-501, 1991.
8. Takano YS, Harmon BV, Kerr JF: Apoptosis induced by mild hyperthermia in human and murine tumour cell lines: A study using electron microscopy and DNA gel electrophoresis. J Pathol 329-336, 1991.
9. Barry MA, Behneke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353-2362, 1992.
10. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992.
11. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993.
12. Brachman DG, Beckett M, Graves D, et al.: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53:3667-3669, 1993.
13. O'Connor PM, Jackman, J, Jondle D, et al.: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780, 1993.
14. Lowe SW, Ruley HE, Jacks T, et al.: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
15. Strasser A, Harris AW, Jacks T, et al.: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339, 1994.
16. Lowe SW, Bodis S, Mcclatchey A, et al.: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
17. Yanagisawa A, Kato Y, Ohtake K, et al.: c-K-ras point mutations in ductectatic-type mucinous cystic neoplasmas of the pancreas. Jpn J Cancer Res 82:1057-1060, 1991.
18. Kaneko H, Misawa S, Horiike S, et al.: TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189-2193, 1995.
19. Jones MH, Nakamura Y: Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 5:89-90, 1992.
20. Ichikawa D, Takahashi T, Hashimoto N, et al.: Multiple primary cancers:Report of a case. Jpn J Cancer Res 87:105-108, 1996.
21. Gyapay G, Morissett J, Vigale A, et al.: The 1993-94 genethon human genetic map. Nature Genet 7:246-339, 1994.
22. Baker SJ, Preisinger AC, Jessup JM, et al.: p53 gene mutations occur in combination with 17p allelic deletion as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990.
23. Baker SJ, Fearon ER, Nigro JM, et al.: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 253:49, 1991.
24. Fisher DE: Apoptosis in cancer therapy:Crossing the threshold. Cell 78:539-542, 1994.
25. Sugano T, Nitta M, Ohmori H, et al.: Nuclear accumulation of p53 in normal human fibroblasts is induced by various cellular stresses which evoke the heat shock response, independently of the cell cycle. Jpn J Cancer Res 86:415-418, 1995.